September 18, 2009
TRANS GENIC INC.
News Release

Launch of Anti Human COPZ1 Monoclonal Antibody
 

We hereby announce that TRANS GENIC INC. has released an anti human COPZ1 monoclonal antibody developed by GANP® Mouse Technology (our unique technology for producing high-affinity antibodies) as a research reagent on September 18, 2009.
 
We are conducting researches to discover cancer specific antibodies which can be used as biomarkers and develop diagnostic methods using them. Having identified COPZ1 as a novel molecular biomarker candidate by using proteome analysis of clinical samples, we decided to commercialize the anti human COPZ1 monoclonal antibody to make it more widely available to researchers.
 
The antibody is expected to contribute to the development of methods for early diagnosis of cancer and various researches for improving outcomes of cancer treatment.
 
Details of the product are as follows.

Product Name Quantity Price (Tax included) Code
Anti Human COPZ1 Monoclonal Antibody
(Clone No. 1H2)		 50 μg 57,750 yen KC451

◆Release Date: September 18, 2009
◆Distribution Method: Sold through our distributors (Cosmo Bio Co., Ltd., Funakoshi Corporation, Wako Pure Chemical Industries, Ltd.)
◆Test Users Wanted
(For more information, please refer to the website.
http://www.transgenic.co.jp/)
◆Product Information: Please click the code on the list and refer to the product data sheet.
◆Reference:

COPZ1
COPZ1 is a protein on membrane of transport vesicle used to transport substances in a cell and involved in protein transport between endoplasmic reticulum and each organelle (e.g. nucleus and mitochondrion). It has been recently revealed that impaired protein transport triggers various diseases. Therefore clarifying the mechanism of protein transport may lead to the establishment of treatment methods of these diseases.
 
Biomarker
A biomarker is a biological substance contained in urine, blood and others and used as an indicator of a certain disease since the level of the substance changes in accordance with disease severity and pathological state of a patient. Clinical test items such as levels of blood sugar, total cholesterol, uric acid, GOT, GPT and γ-GTP are the most commonly known. Measuring the levels of these biomarkers helps us diagnose diseases and select effective treatments.
 
Proteome Analysis
Proteome analysis is a method to examine structure and function of proteins cyclopaedically. It is possible to identify protein changes associated with a particular disease by conducting proteome analysis of clinical samples (e.g. blood and cancerous tissues of a patient). These identified proteins are molecular biomarker candidates useful for researches on diagnostic reagents and drug discovery.
   

For inquiries and information:
Investors Relations of TRANS GENIC INC. Tel. 03-5524-6152
 
PRINT
 BACK